Company Overview - Amgen is one of the largest biotech companies globally, focusing on oncology/hematology, cardiovascular disease, inflammation, bone health, and rare diseases markets [11] - The company has developed significant drugs such as Epogen and Neupogen, and launched next-generation products like Aranesp and Neulasta [11] - Amgen's acquisition of Immunex Corporation provided access to the blockbuster drug Enbrel, although older drugs are facing declining sales due to competition [11] Financial Performance - Amgen has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a solid position in the market [12] - The company has a Value Style Score of B, supported by a forward P/E ratio of 15.68, which is attractive for value investors [12] - For fiscal 2025, three analysts have revised their earnings estimates upwards, with the Zacks Consensus Estimate increasing to $21.28 per share [12] - Amgen has an average earnings surprise of +12.7%, suggesting a positive trend in earnings performance [12] Investment Considerations - With a strong Zacks Rank and favorable Value and VGM Style Scores, Amgen is recommended for investors' consideration [13]

Group 1 - Advantest Corp. (ATEYY) has shown strong year-to-date performance, gaining approximately 50.4%, outperforming the average gain of 30.3% in the Computer and Technology sector [4] - The Zacks Rank for Advantest Corp. is currently 1 (Strong Buy), indicating a positive earnings outlook as the consensus estimate for full-year earnings has increased by 12.2% over the past three months [3] - Advantest Corp. belongs to the Electronics - Measuring Instruments industry, which has an average gain of 43.5% this year, further indicating that ATEYY is performing well compared to its industry peers [5] Group 2 - The Computer and Technology sector includes 611 individual stocks and holds a Zacks Sector Rank of 3, reflecting the performance of various sector groups [2] - SK Telecom (SKM), another stock in the Computer and Technology sector, has also outperformed the sector with a year-to-date return of 32.5% and a Zacks Rank of 1 (Strong Buy) [4][5] - The Wireless Non-US industry, to which SK Telecom belongs, has moved up by 54.3% year to date, indicating strong performance within that specific industry [6]

Company Overview - Chubb Limited, formerly known as ACE Limited, is one of the world's largest providers of property and casualty (P&C) insurance and reinsurance, with a market capitalization of $86 billion [12] - The company has diversified through acquisitions into various specialty lines, including marine, medical risk, excess property, environmental, and terrorism insurance, and operates in 54 countries and territories [12] Investment Ratings - Chubb has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a solid position but not a strong buy [13] - The Value Style Score is also rated B, supported by attractive valuation metrics such as a forward P/E ratio of 11.62, which may appeal to value investors [13] Earnings Estimates - In the last 60 days, five analysts have revised their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.39 to $24.10 per share [13] - Chubb has an average earnings surprise of +13.4%, suggesting a positive trend in earnings performance [13] Investment Consideration - With a solid Zacks Rank and top-tier Value and VGM Style Scores, Chubb is recommended to be on investors' short lists for potential investment opportunities [14]

Company Overview - ResMed (RMD) is a notable stock within the Medical sector, which consists of 929 individual stocks and ranks 10 in the Zacks Sector Rank [2] - ResMed currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Analysis - Year-to-date, ResMed has achieved a return of approximately 7%, outperforming the average gain of 6.3% for the Medical sector [4] - In comparison, Compass Therapeutics, Inc. (CMPX) has returned 14.7% year-to-date, also outperforming the sector [4] - ResMed is part of the Medical - Products industry, which includes 82 companies and currently ranks 155 in the Zacks Industry Rank; this industry has seen an average loss of 5.6% year-to-date, further highlighting ResMed's strong performance [5] Industry Context - The Medical - Biomedical and Genetics industry, which includes Compass Therapeutics, consists of 450 stocks and is currently ranked 90, with a year-to-date increase of 21.1% [6] - Investors are encouraged to monitor both ResMed and Compass Therapeutics for their continued strong performance in the Medical sector [6]

Company Overview - Corporacion America Airports S.A. (CAAP) is part of the Transportation group, which includes 115 companies and is currently ranked 9 in the Zacks Sector Rank [2] - CAAP has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook based on earnings estimates and revisions [3] Performance Analysis - Over the past three months, the Zacks Consensus Estimate for CAAP's full-year earnings has increased by 0.9%, reflecting improved analyst sentiment [4] - CAAP has returned approximately 12% year-to-date, outperforming the average gain of 4.1% in the Transportation group [4] - In the Transportation - Airline industry, which includes 24 companies, CAAP is slightly underperforming with a year-to-date gain compared to the industry's average of 15.1% [6] Comparative Analysis - Freightcar America (RAIL), another stock in the Transportation sector, has a year-to-date return of 4.3% and a Zacks Rank of 2 (Buy) [5] - The Transportation - Equipment and Leasing industry, to which Freightcar America belongs, has gained 18.3% year-to-date, indicating stronger performance compared to CAAP's industry [7]

Core Viewpoint - EverQuote (EVER) is experiencing significant selling pressure, with a 15.6% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst expectations of better-than-previously predicted earnings [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - EVER's current RSI reading of 28.98 suggests that the heavy selling may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for EVER will improve, leading to a 1.5% increase in the consensus EPS estimate over the last 30 days, which often correlates with near-term price appreciation [7]. - EVER holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

分组1 - West Bancorp reported quarterly earnings of $0.61 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, and up from $0.42 per share a year ago, representing an earnings surprise of +7.02% [1] - The company achieved revenues of $27.27 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.53%, compared to year-ago revenues of $22.02 million [2] - West Bancorp has consistently surpassed consensus EPS estimates for the last four quarters [2] 分组2 - The stock has added about 0.6% since the beginning of the year, while the S&P 500 has gained 1.9% [3] - The current consensus EPS estimate for the coming quarter is $0.55 on revenues of $26.5 million, and for the current fiscal year, it is $2.40 on revenues of $112.2 million [7] - The Financial - Savings and Loan industry, to which West Bancorp belongs, is currently in the top 15% of Zacks industries, indicating a favorable outlook [8]

Core Insights - Fabrinet (FN) is expected to report second-quarter fiscal 2026 results on February 2, with revenues projected between $1.05 billion and $1.10 billion and non-GAAP earnings per share anticipated to be between $3.15 and $3.30 [1][8] - The Zacks Consensus Estimate for revenues is $1.08 billion, reflecting a 29.39% increase year-over-year, while the earnings consensus is $3.26 per share, indicating a 24.9% growth from the previous year [2][8] Revenue and Earnings Expectations - The consensus revenue estimate for the fiscal second quarter is $1.08 billion, which represents a significant year-over-year growth of 29.39% [1][2] - The expected earnings per share range is between $3.15 and $3.30, with a consensus estimate of $3.26, showing a growth of 24.9% compared to the same quarter last year [2][8] Business Performance Drivers - Strong performance in the Telecom and Data Center Interconnect (DCI) sectors is anticipated, with telecom revenues increasing by 59% year-over-year in the fiscal first quarter and DCI sales nearly doubling [3] - The High-Performance Computing (HPC) business is also contributing positively, with double-digit revenue growth in the first quarter and increasing customer adoption [4] Market Challenges - The automotive sector is projected to be the only major market without sequential growth, with revenues expected to be flat or slightly lower, which may limit overall performance [5] - Fabrinet faced margin pressure in the first quarter due to foreign exchange headwinds and seasonal merit increases, which may continue to affect margins despite expected revenue-driven operating leverage [6] Earnings Prediction Model - The current model does not predict a definitive earnings beat for Fabrinet, as it has an Earnings ESP of 0.00% and a Zacks Rank of 3, indicating a neutral outlook [7][9]

Core Viewpoint - Cencora (COR) is expected to report strong first-quarter fiscal 2026 results, with positive revenue and earnings growth driven by pharmaceutical utilization trends and specialty-focused assets [1][3][7] Group 1: Financial Estimates - The Zacks Consensus Estimate for revenues is $85.97 billion, reflecting a 5.5% increase from the prior-year quarter [2] - The consensus estimate for earnings is $4.05 per share, indicating an 8.6% improvement from the previous year's figure [2] Group 2: Performance Drivers - Cencora's performance is anticipated to be supported by strong drug volumes and the U.S. Healthcare Solutions segment, which is expected to be the primary earnings driver [3][5][7] - The integration of Retina Consultants of America (RCA) is likely to contribute positively to sales and margins [3][4] Group 3: Segment Analysis - The U.S. Healthcare Solutions segment is projected to generate sales of $76.72 billion, benefiting from specialty distribution and MSO platforms [6][7] - The International Healthcare Solutions segment is expected to maintain growth, with sales estimated at $7.45 billion, supported by stable trends in Europe and World Courier momentum [6][8] Group 4: Margin and Growth Outlook - Margin performance is expected to remain favorable due to mix benefits from specialty distribution and MSO-related services, despite higher interest expenses from acquisition financing [4][5] - Specialty utilization, particularly in Part B drugs, is anticipated to support above-trend operating income growth [5]

分组1 - Kirby reported quarterly earnings of $1.68 per share, exceeding the Zacks Consensus Estimate of $1.62 per share, and up from $1.29 per share a year ago, representing an earnings surprise of +4.03% [1] - The company posted revenues of $851.78 million for the quarter ended December 2025, which missed the Zacks Consensus Estimate by 0.87%, compared to $802.32 million in the same quarter last year [2] - Kirby has surpassed consensus EPS estimates for the last four quarters but has not beaten consensus revenue estimates during the same period [2] 分组2 - Kirby shares have increased by approximately 16.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.53 on revenues of $852.36 million, and for the current fiscal year, it is $7.11 on revenues of $3.52 billion [7] 分组3 - The Transportation - Shipping industry, to which Kirby belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current Zacks Rank for Kirby is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]